Esperion Therapeutics Announces 2024 Annual Meeting of Stockholders

TL;DR

Esperion Therapeutics will hold its 2024 Annual Meeting on May 23, 2024, to vote on director elections, executive compensation, auditor ratification, and stock plan amendments.

AI Summary

Esperion Therapeutics, Inc. (ESPR) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Annual Meeting scheduled for May 23, 2024, as a virtual meeting. Agenda includes election of two Class II director nominees. Stockholders will vote on non-binding advisory approval of executive compensation. Ratification of Ernst & Young LLP as independent registered public accounting firm for FY 2024. Proposal to amend 2022 Stock Option and Incentive Plan to increase shares by 6,250,000.

Why It Matters

For investors and stakeholders tracking Esperion Therapeutics, Inc., this filing contains several important signals. Key decisions regarding board composition and executive pay will be made. Shareholder approval is sought for significant increases in equity available under stock incentive and purchase plans.

Risk Assessment

Risk Level: — Esperion Therapeutics, Inc. shows moderate risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational disclosures that would significantly alter risk assessment.

Analyst Insight

Review the director nominees and executive compensation proposals to understand management's strategic direction and alignment with shareholder interests.

Key Numbers

• 6,250,000 — Shares increase for 2022 Plan (Amendment to increase aggregate shares authorized for issuance under the 2022 Plan.)
• 6,175,000 — Shares increase for ESPP (Amendment to increase shares reserved for issuance under the ESPP.)

Key Players & Entities

• Esperion Therapeutics, Inc. (company) — Registrant
• Ernst & Young LLP (company) — independent registered public accounting firm
• May 23, 2024 (date) — 2024 Annual Meeting date
• 2022 Stock Option and Incentive Plan (plan) — plan to be amended
• 2020 Employee Stock Purchase Plan (plan) — plan to be amended

FAQ

Industry Context

Esperion Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing treatments for cardiovascular diseases.

Regulatory Implications

The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.

What Investors Should Do

1. Review the proposals for director nominees and executive compensation.
2. Evaluate the proposed amendments to the 2022 Stock Option and Incentive Plan and the ESPP.
3. Confirm the ratification of Ernst & Young LLP as the independent auditor.

Key Dates

• 2024-05-23: 2024 Annual Meeting of Stockholders — Key votes on directors, compensation, auditor, and stock plans will occur.

Year-Over-Year Comparison

This is the initial filing for the 2024 proxy season, detailing the agenda for the upcoming annual meeting.

Key Financial Figures

• $0.001 — 7 shares of our common stock, par value $0.001 per share, outstanding as of March 26,

Filing Documents

• esperion-definitive2023pro.htm (DEF 14A) — 944KB
• blookersigv2a.jpg (GRAPHIC) — 5KB
• capnetlossv2a.jpg (GRAPHIC) — 177KB
• captsrv2a.jpg (GRAPHIC) — 175KB
• espe_rmxrgbxfcxpos002a.jpg (GRAPHIC) — 43KB
• proxycard11a.jpg (GRAPHIC) — 103KB
• proxycard12a.jpg (GRAPHIC) — 156KB
• proxycard21a.jpg (GRAPHIC) — 105KB
• proxycard22a.jpg (GRAPHIC) — 83KB
• sheldonsignaturea.jpg (GRAPHIC) — 20KB
• 0001628280-24-015824.txt ( ) — 2135KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 33 RELATED PARTY TRANSACTIONS 44 TRANSACTION OF OTHER BUSINESS 44 HOUSEHOLDING 44 ADDITIONAL INFORMATION 45 ANNEX A - THE ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN AND ITS AMENDMENT S 46 ANNEX B - THE ESPERION THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AND ITS AMENDMENT S 62 Table of Contents IMPORTANT NOTICE REGARDING INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON MAY 23, 2024 We are furnishing proxy materials to our stockholders primarily via the Internet. On or about April 11, 2024, we mailed to our stockholders a Notice of Internet Availability (the "Notice of Internet Availability") containing instructions on how to access our proxy materials, including our Proxy Statement and our Annual Report to Stockholders for the fiscal year ended December 31, 2023 (the 2023 Annual Report). This process allows us to provide our stockholders with the information they need on a more timely basis, while reducing the environmental impact of our annual meeting and lowering the costs of printing and distributing our proxy materials. The Notice of Internet Availability also instructs you on how to submit your proxy or voting instructions through the Internet or to request a paper copy of our proxy materials, including a proxy card and, for shares held in "street name" (i.e., held for your account by a broker, bank or other nominee), a voting instruction form, that includes instructions on how to submit your proxy or voting instructions by mail or telephone. Other stockholders, in accordance with their prior requests, have received e-mail access to our proxy materials and instructions to submit their vote via the Internet, or have been mailed paper copies of our proxy materials and a proxy card or voting instruction form. A copy of our Proxy Statement and our 2023 Annual Rep

View Full Filing

View this DEF 14A filing on SEC EDGAR